Mirum Pharmaceuticals (MIRM) Stock Statistics & Valuation Metrics

Mirum Pharmaceuticals has a market cap or net worth of $5.82B. The enterprise value is $4.80B.

Mirum Pharmaceuticals has 60,981,228 shares outstanding. The number of shares has decreased by -2.65% in one year.

Mirum Pharmaceuticals’s return on equity (ROE) is -0.07 and return on invested capital (ROIC) is -3.46%.

The current PE Ratio of Mirum Pharmaceuticals is ―. Mirum Pharmaceuticals’s PEG ratio is 2.28.

In the last 12 months, Mirum Pharmaceuticals had revenue of 521.31M and earned -23.36M in profits. Earnings per share was -0.47.

In the last 12 months, operating cash flow was -170.97M and capital expenditures -1.58M, giving a free cash flow of -172.55M billion.

Mirum Pharmaceuticals pays an annual dividend of ―, resulting in a dividend yield of ―

Mirum Pharmaceuticals upcoming earnings date is Jul 30, 2026, After Close (Confirmed).

Mirum Pharmaceuticals as a current ratio of 2.67, with Debt / Equity ratio of 133.52%

In the past 12 months, Mirum Pharmaceuticals has paid 1.94M in taxes.

Mirum Pharmaceuticals EV to EBITDA ratio is 231.78, with an EV/FCF ratio of 72.68.

Mirum Pharmaceuticals has $386.26M in cash and marketable securities with $323.78M in debt, giving a net cash position of $62.48M billion.

Gross margin is 81.36%, with operating margin of -4.25%, and net profit margin of -4.48%.

The average price target for Mirum Pharmaceuticals is $145.92, which is 11.43% higher than the current price. The consensus rating is Strong Buy